a test was carried out in accordance with an embodiment of the present invention , and results are shown in table 1 below . peripheral blood was extracted from ten human volunteers for use in ten respective experiments . in each experiment , cells were fractioned from the blood using a ficoll ™ gradient in order to generate a population of peripheral blood mononuclear ( pbmc ) cells as source cells (“ s . cells ”). subsequently , a ccp was generated in accordance with protocols described herein for percoll ™ based enrichment . results in table 1 show enrichment of the percentages of cd34 + cd45 −/ dim cells in the ccp compared to the source cells . enrichment is defined as the percentage of cells having a given characteristic in the ccp , divided by the percentage of cells having that characteristic in the source cells . in a separate set of experiments , in accordance with an embodiment of the present invention , results were obtained as shown in fig1 and table 2 below . peripheral blood was extracted from ten human volunteers for use in ten experiments . a ccp was generated in accordance with protocols described herein ( see example 1 ). results in fig1 and in table 2 show the fluorescent intensity of cd31bright cells in the ccp . cd31 brightness ( dim or bright ) is defined as the ratio between intensity resulting from staining using anti - cd31 fitc - conjugated monoclonal antibodies and intensity resulting from staining using isotype control fitc - conjugated antibodies . fig1 is a graph showing results obtained from ccp cells in one representative experiment , in accordance with an embodiment of the present invention . ccp cells stained using isotype control fitc - conjugated antibodies are represented by the dashed line and ccp cells stained using fitc - conjugated anti - cd31 antibodies are represented by the black line . three different intensity areas were marked : ( a ) m1 — low intensity corresponding to non - specific staining of isotype control or cells that do not express cd31 , located at geometric mean intensity of 5 . 38 ; ( b ) m2 - dim intensity corresponding to cells expressing cd31 at a geometric mean intensity of 46 . 69 ; and ( c ) m3 - bright intensity corresponding to cells expressing cd31 at a geometric mean intensity of 478 . 45 . table 2 is a numerical summary of intensities m1 , m2 and m3 and their respective ratios resulting from ten independent experiments . cd31bright cells ′ ( m3 ) mean intensity is 86 . 5 ( se = 10 . 42 ) times greater than the negative control intensity ( m1 ) and 10 . 69 ( se = 0 . 66 ) times more than cd31dim cells ( m2 ) ( which themselves have an intensity 8 . 00 ( se = 0 . 63 ) times more than m1 ). thus , results indicate that the ccp was enriched to provide cd31 + cells . in a separate set of experiments , in accordance with an embodiment of the present invention , results were obtained as shown in table 3 below . peripheral blood was extracted from nine human volunteers for use in nine experiments . a ccp was generated in accordance with protocols described hereinabove with reference to example 1 . in a separate set of experiments , a human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp ; the ccp was grown on fibronectin or plasma - coated t75 flasks in the presence of medium containing autologous serum (& gt ;= 10 %), 2 ng / ml vegf , and 5 iu / ml heparin . fig2 is a photograph showing the morphology of a typical angiogenic cell precursor ( acp ) population , produced in the experiments of example 3 , in accordance with an embodiment of the present invention . typically , elongated and spindle - shaped cells are observed in cultures of acps . this image was obtained from x200 magnification of cultured acps . in a separate set of experiments , a human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp , as described hereinabove with respect to example 4 . the ccp was grown on fibronectin or plasma - coated t75 flasks in the presence of medium containing autologous serum (& gt ;= 10 %), 2 ng / ml vegf , and 5 iu / ml heparin . fig3 contains photographs of a typical angiogenic cell precursor ( acp ) population , produced in the experiments of example 2 , in accordance with an embodiment of the present invention . harvested cells were loaded on a glass slide and fixed prior to their specific staining stained cells were mounted using a fluorescent mounting solution containing the nuclear stain dapi . figs . a1 - a 3 are a series of photographs from cells stained with fitc - conjugated ulex - lectin , cells stained with pe - conjugated anti - cd31 , or cells that stained with both ulex - lectin and anti - cd31 , in accordance with respective embodiments of the present invention . a1 is a photograph of cells stained with the nuclear marker dapi . a2 is a photograph showing green emission resulting from staining of the same cells with fitc - conjugated ulex - lectin . a3 is a photograph showing red emission resulting from staining of the same cells with pe - conjugated anti - cd31 antibodies . figs . b1 - b 3 are a series of photographs from cells stained with isotype control antibodies , in accordance with respective embodiments of the present invention . b1 is a photograph of cells stained with the nuclear marker dapi , b2 is a photograph showing green emission resulting from staining of the same cells with fitc - conjugated mouse igg antibodies , and b3 is a photograph showing red emission resulting from staining of the same cells with pe - conjugated mouse igg antibodies . typically , acp cells fluoresce both red and green indicating adhesion of both ulex - lectin and anti - cd31 thereto . images were obtained from x200 magnification . in a separate set of experiments , a human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp , as described hereinabove with reference to example 4 . the ccp was grown on fibronectin or plasma - coated t75 flasks in the presence of medium containing autologous serum (& gt ;= 10 %), 2 ng / ml vegf , and 5 iu / ml heparin . fig4 contains photographs of a typical angiogenic cell precursor ( acp ) population , produced in the experiments of example 4 , in accordance with an embodiment of the present invention . harvested cells were loaded on a glass slide and fixed prior to their specific staining stained cells were mounted with a fluorescent mounting solution containing the nuclear stain dapi . figs . a2 - a 3 are a series of photographs demonstrating uptake of ac - ldl , cells stained with anti - cd31 , or cells that show both uptake of ac - ldl and staining with anti - cd31 , in accordance with respective embodiments of the present invention . a1 is a photograph of cells stained with the nuclear marker dapi , a2 is a photograph showing green emission resulting from uptake of fitc labeled - ac - ldl by the same cells , and a3 is a photograph showing red emission resulting from staining of the same cells with pe - conjugated anti - cd31 antibodies . figs . b1 - b 3 are a series of photographs from cells stained with isotype control antibodies , in accordance with an embodiment of the present invention . b1 is a photograph of cells stained with the nuclear marker dapi , b2 is a photograph showing green emission resulting from staining of the same cells with fitc - conjugated mouse igg antibodies , and a3 is a photograph showing red emission resulting from staining of the same cells with pe - conjugated mouse igg antibodies . typically , acp cells fluoresce both green and red indicating that acps uptake ac - ldl as well as comprise cd31 . images were obtained from x200 magnification . in the same set of experiments , the human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp as described hereinabove with respect to example 4 . flow - cytometry percentage staining results from nine independent experiments are summarized in table 4 , and show the average staining results obtained on day 5 of culturing . results using such a protocol typically yield a pcp having an average of 60 . 7 % of cells that both demonstrate uptake of ac - ldl and stain for cd31bright . in a separate set of experiments , a human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp , as described hereinabove with respect to example 4 . harvested acp - rich pcp cells were washed from culture medium and incubated for 24 hours in a serum - free medium . average secretion levels ( pg / ml ) of il - 8 , vegf , and angiogenin as obtained from four independent experiments are summarized in table 5 . in the same set of experiments , a human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp , as described hereinabove with reference to example 4 . angiogenic pattern and vascular tube formation of acp - rich pcp cells were examined microscopically following plating of the cells on an extracellular matrix gel ( ecm ). typically , semi - closed and closed polygons of capillaries and complex mesh - like capillary structures were observed and scored according to a scale published by kayisli et al . ( 52 ) as grade 4 - 5 , indicating the angiogenic - inducing properties of the acp - rich pcp . fig5 is a photograph showing tube formation in an acps , produced in the experiments of example 6 , in accordance with an embodiment of the present invention . typical mesh - like capillary structures generated from a harvested acps are present in the culture and are suitable for administration to a human . in a separate set of experiments , a human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp ; the ccp was grown on fibronectin or plasma - coated t75 flasks in the presence of medium containing autologous serum (& gt ;= 10 %), 2 - 10 ng / ml vegf , and 5 iu / ml heparin . at the end of the culturing period , acp cells were harvested and labeled with 0 . 8 ug / ml ac - ldl - dio for 15 min at 37 c and placed in inserts which were placed in wells . one million labeled acps were placed on microporous membrane inserts with a pore size of 8 micrometer . 200 ul medium was placed at the bottom of each of the wells . negative control ( m199 ), positive control ( e . g ., 20 ng / ml vegf , 20 ng / ml bfgf , and 20 ng / ml scf ) and 0 . 08 - 60 ng / ml human recombinant interleukin - 8 ( hil - 8 ) diluted in m199 medium were plated in respective wells and the acp cells were allowed to migrate toward each respective medium . following 1 hour incubation in the presence of the negative control medium , the positive control medium , and the il - 8 containing media , labeled migrating cells from 10 - 15 random microscopic fields were evaluated using fluorescent microscope and automated counting software ( nih imagej ). calculation of cell number per 1 mm ̂ 2 was based on area of counting field ( x20 ) which equals 0 . 178 mm ̂ 2 , and each mm ̂ 2 contains 5 . 62 fields . assessment of acp migratory potential indicated that acps migrate toward chemokines such as vegf , bfgf , scf , and hil - 8 in a manner dependent on respective concentrations thereof , e . g ., hil - 8 concentration of typically higher than 6 . 7 ng / ml induces substantial migration of acps , and hil - 8 concentrations of about 7 - 20 ng / ml typically induce substantial migration of acps . fig6 a and 6b are graphs showing results obtained in five experiments of example 10 , in accordance with an embodiment of the present invention . fig6 a shows migration toward negative and positive control media of ac - ldl - dio pre - labeled acps . fig6 b shows a dosage - dependence curve reflecting migration of ac - ldl - dio pre - labeled acps in response to increasing concentrations of hil - 8 acps derived from the human - pbmc - derived ccp show statistically significant migration toward the positive control samples . moreover , acp migration corresponding to increasing hil - 8 doses was observed . dose - dependent acp migration peaked at 6 . 7 - 20 ng / ml of hil - 8 . in a separate set of experiments , the human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp , as described hereinabove with reference to examples 4 or 10 . in some embodiments , generation of the acp - rich pcp is attributed to migration of acp cells to a specific chemokine , in combination with the differentiation of ccp cells . migratory potential of acp - rich pcp was measured as described hereinabove with respect to example 10 . in this example , a conditioned medium ( cm ) was generated using the patients &# 39 ; cells which secrete chemokines into the medium . the patients &# 39 ; cells were then extracted from the medium , leaving a chemokine - rich medium for subsequent plating of acp therein . the potential for acp migration in response to chemokines was then assessed when the acps were incubated for 1 hour with conditioned medium . following 1 hour incubation in the presence of negative control ( m199 ); 20 ng / ml hil - 8 ; or cm ( at concentrations of 2 - 20 ng / ml ), migration of labeled cells from 10 - 15 random microscopic fields was evaluated using a fluorescent microscope and automated counting software ( nih imagej ). calculation of cell number per 1 mm ̂ 2 is based on area of counting field ( x20 )= 0 . 148 mm ̂ 2 and thus each square millimeter contains 6 . 7 fields . it was determined that acps migrate toward chemokines secreted during the production of the acp - rich pcp . for some applications , the generated acp - rich pcp batches were used to treat cardiovascular patients . all patients treated with these batches showed more than 10 % improvement in left - ventricular - ejection fraction both 3 and 6 months following treatment . it is hypothesized that this improvement was enabled at least in part by the migration of acps to the vicinity . fig7 is a graph showing results obtained in four experiments of example 11 , in accordance with an embodiment of the present invention . the acps derived from the human - pbmc - derived ccp show statistically significant migration toward the conditioned medium containing secreted chemokines ; this medium was generated in the process of the production of acp - rich pcp . in a separate set of experiments , migratory potential of human - pbmc toward hil - 8 was measured . in vitro assessment of pbmc migratory capability in response to hil - 8 was used to determine the potential of il - 8 to mobilize blood derived stem / progenitor cells from peripheral blood to locations in which high concentrations of il - 8 are expressed in vivo . peripheral blood was extracted from six human volunteers for use in six respective experiments . in each experiment , a ficoll ™ gradient was used to generate a population of pbmcs . one million pbmcs were placed on 3 um pore size microporous membrane inserts which were placed in wells . 200 ul medium was placed at the bottom of each of the wells . negative control ( m199 ) and positive control ( 20 ng / ml hil - 8 ) diluted in m199 medium were plated in respective wells and the pbmcs cells were allowed to migrate toward each respective medium . following 1 hour incubation in the presence of the negative control medium and the positive control medium , migration of cells from 10 - 15 random microscopic fields was evaluated using a fluorescent microscope and automated counting software ( nih imagej ). calculation of cell number per 1 mm ̂ 2 is based on area of counting field ( x20 ) which equals 0 . 148 mm ̂ 2 , and each square millimeter contains 6 . 7 fields . it was determined that hil - 8 induced mobilization of only a small fraction of the pbmcs , probably the stem / progenitor cells . fig8 is a graph of migration of pbmcs in response to hil - 8 , in accordance with an embodiment of the present invention . the results were obtained from six experiments ( example 12 ), and show that stem / progenitor cells derived from human - pbmcs migrate toward hil - 8 . reference is now made to fig9 a and 9b which are graphs showing results obtained in the experiments following injection into rats of acp - rich pcps derived from a human - pbmc - derived ccp ( as described hereinabove with respect to example 4 ) following acute myocardial infarction , in accordance with an embodiment of the present invention . the human - pbmc - derived ccp was cultured in order to generate an acp - rich pcp as described in example 4 . acp - rich pcp therapeutic potential was then assessed in a rat model of acute myocardial infarction which was induced in 15 male nude rats ( 200 - 225 g ) by ligation of the left anterior descending ( lad ) artery . six days after myocardial infarction , 10 rats were injected with 1 . 5 × 10 ̂ 6 acp - enriched cells ( acp , n = 10 ), while 5 rats were injected with the culture medium ( control , n = 5 ), via the aortic arch . cardiac function ( ejection fraction ) and the ratio of necrotic scar area to left ventricular free wall area were measured 28 days following the acp - rich pcp and the culture medium administrations . it is to be noted that the percentage of ejection fraction of the acp - administered rats , as represented by fig9 a , increased substantially in comparison to the decreased percentage ejection fraction of the control rats . additionally , a percentage reduction of necrotic tissue was observed in the acp - administered rats in comparison to the percentage of necrotic tissue observed in the control rats . paraffin fixed tissue sections obtained from the 10 acp - administered rats were stained in order to trace engrafted human cells and cardiomyocyte ( cmc ) markers in the border area of the scar tissue . fig9 c , 9d and 9e are photographs showing typical sections taken from a heart of one of the 10 rats 28 days after the injection of the acps derived from a human - pbmc - derived ccp in the experiments of the present example ( example 13 ) in accordance with an embodiment of the present invention . fig9 c shows staining of the rat &# 39 ; s heart cells with anti - human mitochondria . fig9 d shows the cells stained for cmc markers ( myosin heavy chain ( mhc )), fig9 e shows the rat heart cells stained for cardiac troponin i . ( reference is again made to fig9 c - e . the stained cells are marked by arrows ). these results depicted in fig9 c - d demonstrate that the human acps , derived in accordance with an embodiment of the present invention from the hpbmc - derived ccp , homed to damaged cardiac tissues , engrafted , and is hypothesized to have transdifferentiated into cells expressing cardiomyocyte markers . it is to be noted that acps typically improve systemic endothelial functioning , as expressed by improved ejection fraction and reduced necrosis . particular examples of improvement due to administration of acps , derived in accordance with an embodiment of the present invention , include improved cardiovascular functioning and improved sexual functioning . the scope of the present invention includes identifying a patient having cardiovascular dysfunction or sexual dysfunction , and administering acps to the patient in order to treat the dysfunction . in a production procedure , individual autologous human - pbmc - derived ccps were cultured in order to generate an acp - rich pcp , as described hereinabove . the ccps were grown on autologous plasma - coated t75 flasks in the presence of medium containing autologous serum (& gt ;= 10 %), 2 - 10 ng / ml vegf , and 5 iu / ml heparin . harvested cells , approved by quality control for clinical use , were administrated to patients . the therapeutic potential of acp - rich pcp is summarized in results of administration thereof to 14 patients suffering from end - stage heart failure . left ventricular ejection fraction ( ef ) and disease severity score ( score ) were assessed prior to and 1 - 8 months after the acp cell administration . improvement of these parameters was calculated relative to each patient &# 39 ; s baseline evaluation according to the following equation : results show statistically significant improvement ( p & lt ; 0 . 0001 ; tested using two - tailed , paired t test analysis ) in both parameters following treatment by administering acp - rich pcp . table 6 shows the number of treated patients , averages and individual results relating to ef and disease severity score , as well as the calculated percent improvement thereof . in a separate set of experiments , a human - pbmc - derived ccp was cultured in order to generate a cardiomyocyte ( cmc )- rich pcp ; the ccp was grown on fibronectin or plasma - coated t75 flasks in accordance with protocols described herein ( see medium preparation ). fig1 is a photograph of a typical cmc - rich pcp from the experiments of the current example ( example 15 ), derived in accordance with an embodiment of the present invention . typically , these cells appear elongated with dark cytoplasm , which may indicate high protein content . this image was obtained from x200 magnification of cultured cmc - rich pcp cells . fig1 a , 11b , and 11c are photographs showing immunostaining of ccp - derived cardiomyocytes in the experiments of the current example ( example 15 ), in accordance with an embodiment of the present invention . slide - fixed cmc pcp cells were stained with : cells stained with non - specific mouse igg were detected by anti - mouse igg - fitc or by anti - mouse igg - cy3 and were used as negative controls . fig1 a - c show that cmc - rich pcp cells expressed the typical cardiomyocyte cellular markers : cardiac troponin t ( fig1 a ), alpha - actin ( fig1 b ), as well as the functionally important gap junction marker connexin - 43 ( fig1 c ). the images were obtained from x100 magnification of slide - fixed cells . in the same set of experiments that produced the results shown in fig1 - 11c , a human - pbmc - derived ccp was cultured in order to generate a cmc - rich pcp ; the ccp was grown on fibronectin or plasma - coated t75 flasks in accordance with protocols described herein ( see medium preparation ). fig1 a and 12b are graphs showing flow cytometry analysis results obtained from immunostaining of a cmc - rich pcp in the experiments of the current example ( example 16 ), in accordance with respective embodiments of the present invention . in fig1 a - b , lines describing control , e . g ., non - specific staining , are marked as “ control ”; specific immunostaining with the cardiac cellular markers desmin and troponin t are marked as desmin ( fig1 a ) and troponin t ( fig1 b ), respectively . the m1 line represents the statistical marker area in which the cells are positively stained for the respective marker . in a separate set of experiments , a human - pbmc - derived ccp was cultured in order to generate a cmc - rich pcp , as described hereinabove . the cmc - rich pcp cells &# 39 ; therapeutic potential was assessed in a rat model of acute myocardial infarction . cmc - rich pcp cells were used for implantation into a rat model of induced acute myocardial infarction as described hereinabove with respect to example 13 ( with the exception that cmc - rich pcp cells were used for implantation into the rat model in the current example , whereas in example 13 , acp - rich pcp cells were used for implantation ). six days after myocardial infarction , heart muscle of 9 rats were injected with 1 . 5 × 10 ̂ 6 cmc pcp cells ( cmc , n = 9 ), while heart muscle of 5 rats were injected with culture medium ( control , n = 5 ). cardiac function ( ejection fraction ) was evaluated 14 days following the administration of the cmc - rich pcp cells or culture medium . fig1 is a graph showing experimental results obtained in the experiments of example 13 , in accordance with another embodiment of the present invention . it is to be noted that the percentage of ejection fraction of the cmc - administered rats increased substantially in comparison to the decreased percentage ejection fraction of the control rats . a series of protocols are described hereinbelow which may be used , as appropriate , separately or in combination with examples 1 - 17 , in accordance with embodiments of the present invention . it is to be appreciated that numerical values are provided by way of illustration and not limitation . typically , but not necessarily , protocols may be derived using values selected from a range of values that is within 20 % of the value shown . similarly , although certain steps are described herein with a high level of specificity , a person of ordinary skill in the art will appreciate that additional or other steps may be performed , mutatis mutandis . in accordance with an embodiment of the present invention , generation of a single - cell suspension is carried out using the following protocols : receive blood bag and sterilize it with 70 % alcohol . load blood cells onto a ficoll ™ gradient . spin the tubes for 20 minutes at 1050 g at room temperature ( rt ), with no brake . collect most of the plasma from the supernatant . collect the white blood cell fraction from every tube . transfer the collected cells to a new 50 ml tube , adjust volume to 30 ml per tube using pbs . spin tubes for 15 minutes at 580 g , rt , and discard supernatant . count cells in trypan blue . re - suspend in culture medium comprising , for example , x - vivo 15 ™. isolate 10 cm umbilical cord . wash thoroughly with sterile pbs . identify the major vein of the cord , and clamp one end of the vein . wash twice with 30 ml sterile pbs . fill vein with 0 . 15 % collagenase ( about 5 ml of 0 . 15 % collagenase solution ). clamp the second end of the vein . incubate at 37 c for 15 min . wash outer side of the cord with 70 % ethanol . release the clamp from one end of the vein and collect the cell suspension . centrifuge for 10 min at 580 g , 21 c . re - suspend the cells in culture medium comprising , for example , x - vivo 15 ™, 10 % autologous serum , 5 iu / ml heparin , and one or more growth factors . get bone marrow aspiration from surgical room . re - suspend in culture medium comprising , for example , x - vivo 15 ™, 10 % autologous serum , 5 iu / ml heparin , and one or more growth factors . pass suspension through a 200 um mesh . in accordance with an embodiment of the present invention , generation of a ccp is carried out using the following protocols : protocol 1 : generation of a human ccp from pbmcs using a percoll ™ gradient . prepare gradient by mixing a ratio of 5 . 55 percoll ™ ( 1 . 13 g / ml ): 3 . 6 ddh2o : 1 pbsx10 . for every 50 ml tube of percoll : mix 20 ml of percoll ™ stock , 13 ml of ddh2o and 3 . 6 ml of pbsx10 . mix vigorously , by vortexing , for at least 1 min . load 34 ml mix into each 50 ml tube . centrifuge tubes , in a fixed angle rotor , for 30 min at 17 , 000 g , 21 c , with no brake . gently layer 3 . 0 ml of cell suspension of 150 million - 400 million pbmcs on top of the gradient . prepare a second tube with density marker beads : gently layer 3 . 0 ml of medium on top of the gradient . gently load density marker beads — 10 ul from each bead type . centrifuge tubes , in a swinging bucket rotor , for 30 min at 1260 g at 13 c , with no brake . gently collect all bands located above the red beads , and transfer to tube with 10 ml medium . centrifuge cells for 15 min at 580 g at 21 c . discard supernatant and re - suspend pellet in medium . count cells in trypan blue . centrifuge cells for 10 min at 390 g , 21 c . discard supernatant and re - suspend pellet in medium . take ccp cells for facs staining protocol 2 : generation of human ccp from pbmcs using an optiprep ™ gradient . take up to 130 million cells for each enrichment tube . spin cells for 10 min at 394 g , 21 c . suspend cell pellet in 10 ml of donor serum . prepare a 1 . 068 g / ml optiprep ™ gradient by mixing a ratio of 1 optiprep ™: 4 . 1 pbs . for every 50 ml enrichment tube : mix 10 ml of cell suspension with 4 ml optiprep ™. for preparation of a 1 . 068 g / ml optiprep ™ gradient , mix 5 ml of optiprep ™ and 20 . 5 ml of pbs . gently layer 20 ml of the 1 . 068 g / ml gradient on top of the cell suspension . gently layer 1 . 5 ml hank &# 39 ; s buffered saline ( hbs ) on top of the gradient layer . centrifuge for 30 min at 700 g at 4 c , with no brake . gently collect the layer of cells that floats to the top of the 1 . 068 g / ml optiprep ™ gradient into a 50 ml tube pre - filled with pbs . centrifuge for 10 min at 394 g , 21 c . discard supernatant and re - suspend pellet in medium . count cells in trypan blue . it is to be noted that culture containers are typically either un - coated or coated with one or a combination of acp - enhancing materials such as collagen , fibronectin , cd34 , cd133 , tie - 2 , or anti - cd117 . in accordance with an embodiment of the present invention , the coating of a tissue culture container is carried out using the following protocols : for 20 t75 flasks — prepare up to seven days before , or on day of pbmc preparation . prepare 50 ml of 25 ug / ml fibronectin solution in pbs . fill every flask with 2 - 5 ml fibronectin 25 ug / ml . incubate at 37 c for at least 30 min . collect fibronectin solution . wash flask twice in pbs . dry flasks keep dry flasks at room temperature . dried flasks can be saved for one week at room temperature ( rt ). protocol 2 : coating t75 flasks with 25 ug / ml fibronectin and 5 ng / ml bdnf coat flasks with fibronectin 25 tg / ml , as described in protocol 1 . prepare 50 ml of 5 ng / ml bdnf solution in pbs . after washing off fibronectin , fill every flask with 2 - 5 ml bdnf 10 ng / ml . incubate at 37 c for 1 hour . collect the solution . wash flask twice in 10 ml pbs . keep dry flasks at room temperature until use . in accordance with an embodiment of the present invention , serum preparation is carried out using the following protocol : ( serum can be obtained directly or prepared from plasma ). take 100 ml of undiluted blood . spin at 1100 g ( 2500 rpm ) for 10 min . transfer the upper layer ( plasma ) to a new 50 ml tube . add 1 . 0 ml 0 . 8m cac1 2 - 2h 2 o for every 40 ml plasma . incubate for 0 . 5 - 3 hours at 37 c . spin coagulated plasma 5 min at 2500 g . collect the serum in a new tube , avoiding clotting . aliquot collected serum and save at - 20 c until use . in accordance with an embodiment of the present invention , medium preparation is carried out using the following protocols : medium can contain one or more additives , such as lif , epo , igf , b - fgf , m - csf , gm - csf , tgf alpha , tgf beta , vegf , bha , bdnf , ngf , egf , nt3 , nt4 / 5 , gdnf , s - 100 , cntf , ngf3 , cfn , admif , estrogen , progesterone , cortisone , cortisol , dexamethasone , or any other molecule from the steroid family , prolactin , an adrenocorticoid hormone , acth , glutamate , serotonin , acetylcholine , no , retinoic acid ( ra ) or any other vitamin d derivative , heparin , insulin , forskolin , simvastatin , mcdb - 201 , mct - 165 , glatiramer acetate , a glatiramer acetate - like molecule , ifn alpha , ifn beta or any other immunoregulatory agent sodium selenite , linoleic acid , ascorbic acid , transferrin , 5 - azacytidine , pdgf , vegf , cardiotrophin , and thrombin or rosiglitazone in various concentrations , typically ranging from about 100 pg / ml to about 100 μg / ml ( or molar equivalents ). typically , medium should not be used more than 10 days from its preparation date . protocol 1 : medium for enhancement of ccp - derived angiogenic cell precursors ( acps ). serum - free medium ( e . g ., x - vivo 15 ™) 10 % autologous serum 5 iu / ml heparin 5 ng / ml vegf 1 ng / ml epo serum - free medium ( e . g ., x - vivo 15 ™) 20 ng / ml bfgf 50 ng / ml ngf 200 um bha ( this is added during the last 24 hours of culturing ) 10 ng / ml ifn beta 10 ug / ml glatiramer acetate 10 um forskolin 1 um cortisone 1 ug / ml insulin serum - free medium ( e . g ., x - vivo 15 ™) 20 ng / ml bfgf 50 ng / ml ngf 25 ng / ml bdnf 200 um bha ( this is added during the last 24 hours of culturing ) serum - free medium ( e . g ., x - vivo 15 ™)) 10 % autologous serum 5 iu / ml heparin 10 ng / ml egf 20 ng / ml bfgf 10 ug / ml glatiramer acetate 50 ng / ml ngf3 protocol 4a . medium for enhancement of ccp - derived cardiomyocyte ( cmc ) progenitor cells . step i serum - free medium ( e . g ., x - vivo 15 ™ 10 % autologous serum 20 ng / ml bfgf 20 ug / ml ifn beta 5 iu heparin . step ii five to ten days after culture onset , add 3 um 5 - azacytidine for 24 hours . serum free medium dmem - low glucose 20 % autologous serum 10 % mcdb - 201 2 ug / ml insulin 2 ug / ml transferin 10 ng / ml sodium selenite 50 mg / ml bsa 1 nm dexamethasone 20 ug / ml glatiramer acetate 0 . 47 ug / ml linoleic acid 0 . 1 mm ascorbic acid 100 u / ml penicillin in accordance with an embodiment of the present invention , conditioned medium preparation is carried out using the following protocol : protocol 1 : preparation of 100 ml enriched medium containing 10 % autologous conditioned medium . extraction of tissue pieces for co - culture : dissection of rat blood vessels ( other non - human or human tissues may also be used ): anesthetize animal using anesthetic reagents ( e . g ., 60 - 70 % co2 , isoflurane , benzocaine , etc .). lay animal on its back and fix it to an operating table . using sterile scissors , cut animal &# 39 ; s skin and expose the inner dermis . using a second set of sterile scissors , cut the dermis , cut chest bones , and expose the heart and aorta . cut small pieces , 0 . 2 - 1 cm long , from the aorta and other blood vessels , and place them in a container pre - filled with 50 ml cold culture medium ( e . g . rpmi , x - vivo 15 ™, or any other growth medium ). using forceps and scissors , clean tissue sections , to remove outer layers such as muscle , fat , and connective tissue . using forceps and scalpel , cut each blood vessel along its length , and expose the inner layer of endothelial cells . using forceps and scalpel , cut small pieces of up to 0 . 1 cm2 from the tissue . it is to be understood that whereas this technique is in accordance with one embodiment of the present invention , the scope of the present invention includes extracting a blood vessel from a human , as well . for example , an incision may be made over the saphenous vein , in order to facilitate dissection of a distal 1 cm portion of the vein . tributary veins thereto are tied and transected . distal and proximal ends of the 1 cm portion of the saphenous vein are tied , and the vein is harvested . use the dissected tissue for direct and / or indirect co - culturing with the ccp and / or to generate conditioned medium . lay dissected pieces in culture containers , for example in t75 flasks , or 50 ml tubes . optionally , fill with cell culture medium containing 0 . 1 - 3 ug / ml or 3 - 100 ug / ml apoptotic reagent ( such as valinomycin , etoposide or staurosporine ), until all pieces are covered . refresh culture medium every 2 days . collect this medium ( now conditioned medium ) into 50 ml tubes . spin collected conditioned medium at 450 g for 10 min , at room temperature . collect supernatant in a new sterile container . details regarding preservation of the conditioned medium , in accordance with an embodiment of the present invention , are described hereinbelow . in accordance with an embodiment of the present invention , culturing of a ccp to produce a pcp is carried out using the following protocols : spin suspension for 15 minutes at 450 g , 21 c . discard the supernatant . gently , mix cell pellet and re - suspend the ccp cells . re - suspend pellet to 10 million ccp cells / ml . fill t75 flask with 15 ml enriched medium , and add 5 ml of 10 million ccp cells / ml to attain a final concentration of 50 million ccp cells / flask . incubate t75 flasks , plates and slides at 37 c , 5 % co2 . for some applications , increased expansion and / or differentiation of the ccp may be obtained by exposure of the cell culture to oxygen starvation , e . g ., 0 . 1 - 5 % or 5 - 15 % oxygen ( hypoxia ), for 2 - 12 or 12 - 48 hours . this is typically done one or more times , at different points during cell culturing . set the oxygen pressure at 0 . 1 %, and maintain it at this level for 24 hours . remove the flasks from the incubator and examine the culture . take a sample of ccp cells and test viability by trypan blue exclusion method . set the oxygen pressure of the incubator at 20 %. re - insert the flasks into the incubator and continue incubation for the rest of the period . this procedure can be repeated , for example , once a week during the culture period and / or within 24 , 48 , or 72 hours before termination of the culture . for some applications , increased expansion and differentiation of the ccp may be achieved by re - seeding collected cells on new pre - coated dishes in culture medium . collect all cultured ccp in tubes . spin tubes for 10 minutes at 450 g , 21 c . discard the supernatant . gently mix pellet and re - suspend cells in 10 ml fresh medium per t75 flask . seed suspended cells in new pre - coated t75 flasks . continue culturing the cells , and perform all other activities ( e . g ., medium refreshment , visual inspection , and / or flow cytometry ), as appropriate , as described herein . this procedure can be performed weekly during the culture period and / or within 24 , 48 , or 72 hours before termination of the culture . in accordance with an embodiment of the present invention , co - culturing of ccp with tissue - derived conditioned medium is carried out using the following protocol : protocol 1 : culturing of ccp in the presence of conditioned medium derived from a blood vessel culture . spin ccp cells for 15 minutes at 500 g , 21 c . discard the supernatant . gently mix cell pellet and re - suspend cells to 5 - 50 million / ml in autologous medium containing 1 - 20 % autologous serum and / or 1 - 20 % conditioned medium . seed flasks with 2 - 5 million ccp cells / ml . incubate flasks at 37 c , 5 % co2 . after first three days of culture , non - adherent cells can be removed from the culture . in accordance with an embodiment of the present invention , refreshing of the media in ongoing growing ccp cultures is carried out using the following protocol : refreshing of the media in ongoing growing flasks should occur every 3 - 4 days . collect non - adherent cells in 50 ml tubes . fill every flask with 10 ml fresh culture medium enriched with conditioned medium . spin tubes for 10 minutes at 450 g , rt ; discard the supernatant . gently mix cell pellet and re - suspend cells in 10 ml / flask fresh culture medium enriched with condition medium . return 5 ml of cell suspension to every flask . in accordance with an embodiment of the present invention , indirect co - culture of ccp cells with tissue dissection is carried out using the following protocol : protocol 1 : indirect co - culture of dissected blood vessel and ccp cells in a semi - permeable membrane apparatus . lay dissected tissue pieces in the upper chamber of the apparatus on top of the semi - permeable membrane . implant ccp cells in lower chamber . lower chamber can be pre - coated with growth - enhancing molecules such as collagen , plasma , fibronectin , a growth factor , tissue - derived extra cellular matrix and an antibody . refresh culture medium in the upper chamber — aspirate conditioned medium into 50 ml tubes and add autologous culture medium . preserve collected conditioned medium at - 20 c . remove upper chamber after four days of co - culture . refresh culture medium of the ccp cells with culture medium containing 1 - 20 % autologous serum and / or 1 - 20 % conditioned medium . continue growing and harvesting as described herein . co - culture in separate chambers within a culture container in accordance with an embodiment of the present invention , co - culturing within a culture container is carried out using the following protocol : protocol 1 : direct co - culturing of autologous dissected blood vessel and ccp cells . lay dissected tissue pieces in pre - coated flasks . implant ccp cells in pre coated second chamber . using forceps , take out tissue pieces after four days of co - culture . refresh culture medium of the ccp cells with culture medium containing 1 - 20 % autologous serum and / or 1 - 20 % condition medium . continue growing and harvesting as described herein . in accordance with an embodiment of the present invention , harvesting of the cellular product is carried out using the following protocol : collect cells in 50 ml tubes . carefully wash flask surface by pipetting with cold pbs to detach adherent cells . collect washed adherent cells to 50 ml tubes . add 5 ml of cold pbs . detach remaining adherent cells using gentle movements with cell scraper . collect the detached cells and add them to the tubes optionally , add 5 ml edta to each flask and incubate at 37 c for 5 min . collect the detached cells and add them to the tubes spin tubes for 5 min , at 450 g , room temperature . re - suspend the pellets in 2 - 5 ml pbs . count the cells in trypan blue . in accordance with an embodiment of the present invention , cellular product preservation is carried out using the following protocols : cellular product can be kept in preservation media or frozen in freezing buffer until use for transplantation into a patient . prepare freezing buffer containing 90 % human autologous serum and 10 % dmso . suspend cellular product in freezing buffer and freeze in liquid nitrogen . prepare preservation medium including growth medium containing 1 - 20 % autologous serum , with few or no other additives . maintain preservation medium with cellular product at 2 - 12 c in accordance with an embodiment of the present invention , conditioned medium collection and preservation is carried out using the following protocol : conditioned medium can be kept until use for growth medium preparation . conditioned medium should be collected under sterile conditions . spin collected conditioned medium for 10 min at 450 g , 21 c . collect supernatant in a new sterile container . filter supernatant through a 22 um membrane . aliquot conditioned medium to 10 and / or 50 ml sterile tubes , pre - marked with donor details . keep at − 20 c until use . in accordance with an embodiment of the present invention , facs staining is carried out using the following protocol : in accordance with an embodiment of the present invention , immunohistochemistry staining ( ihc ) is carried out using the following protocols : in accordance with an embodiment of the present invention , a tube formation assay is carried out using the following protocol : tube formation was tested using the ecm625 ( chemicon ) in vitro angiogenesis assay kit . angiogenic pattern and vascular tube formation was numerically scored as described by kayisli u . a . et al . 2005 ( 52 ). in accordance with an embodiment of the present invention , secretion of cytokines from harvested cells is assessed using the following protocols : culture 0 . 5 - 1 × 10 ̂ 6 cells / ml over night in 24 well plates in serum - free medium ( e . g ., x - vivo 15 ) collect culture supernatant and spin at 1400 rpm for 5 minutes transfer supernatant to an eppendorf tube and freeze at - 80 c until ready to test cytokine secretion . a commercial duoset cxcr8 / il - 8 ( r & amp ; d systems ) was used for the detection of il - 8 secretion . a commercial cytometric bead array ( cba ) kit for human angiogenesis ( bd 558014 ) was used for the detection of il - 8 , vegf , tnf and angiogenin secretion . it is to be noted that the scope of the present invention includes injecting il - 8 into a human patient in order to recruit acp cells to a given destination within a given patient , in accordance with the needs of the patient . for some applications , techniques described herein are practiced in combination with techniques described in one or more of the references cited in the background section and cross - references section of the present patent application . all references cited herein , including patents , patent applications , and articles , are incorporated herein by reference . it is to be appreciated that by way of illustration and not limitation , techniques are described herein with respect to cells derived from an animal source . the scope of the present invention includes performing the techniques described herein using a ccp derived from non - animal cells ( e . g ., plant cells ), mutatis mutandis . it will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove . rather , the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove , as well as variations and modifications thereof that are not in the prior art , which would occur to persons skilled in the art upon reading the foregoing description .
provided are methods for producing progenitor / precursor cells from a population of initiating cells that have a density of less than 1 . 072 g / ml and at least 25 % of which are cd31bright by in vitro stimulating the icp with different factors .